- It may interest you: The FDA authorizes a third dose of Pfizer and Moderna vaccine for high-risk people
Today, FDA approved the first COVID-19 vaccine for the prevention of # COVID19 disease in individuals 16 years of age and older. https://t.co/iOqsxXV1fj – US FDA (@US_FDA) August 23, 2021
Mandatory vaccination, possible effect of approving the Pfizer / BioNTech vaccine“No one can now argue with the effectiveness and safety of these vaccines ,” Dr. Anthony Fauci , director of the National Institute of Allergy and Infectious Diseases (NIAID), told CNN. “They were very careful to analyze all the information,” added Fauci, who believes the approval would encourage “20-30%” of unvaccinated people to get vaccinated. In addition, he believes that this will lead to many companies, universities and organizations imposing vaccination as a requirement .
- Read also: Huélum! Poli scientist develops 90% effective drug against COVID-19
Pfizer competition will have more obstaclesPfizer’s achievement closes the door for other drug companies to apply to the FDA for new authorizations for emergency use, because this is only possible while other fully approved options are not available. Of course, this is a huge business advantage for Pfizer and BioNTech . If other competitors, such as Moderna or AstraZeneca , want to market their vaccine, they will have to wait for a longer approval process. According to the statement, the Pfizer / BioNTech coronavirus vaccine will be marketed under the name Comirnaty . So far no more details have been released, such as the expected price to the public , points of sale or if there will be any requirement to buy it .
Who can get the Pfizer / BioNTech vaccine?In mid-December 2020, the Pfizer / BioNTech vaccine was licensed for emergency use in the United States for individuals age 16 and older. In May 2021, the authorization was extended to those over 12 years of age, always under the supervision of the health authorities.
In the United States, there are more than 170 million people fully vaccinated against covid-19. Of these, more than 92 million (about 54%) have received the Pfizer / BioNTech vaccine.